vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and Forestar Group Inc. (FOR). Click either name above to swap in a different company.

CLOVER HEALTH INVESTMENTS, CORP. is the larger business by last-quarter revenue ($487.7M vs $273.0M, roughly 1.8× Forestar Group Inc.). Forestar Group Inc. runs the higher net margin — 5.6% vs -10.1%, a 15.8% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs 9.0%). CLOVER HEALTH INVESTMENTS, CORP. produced more free cash flow last quarter ($-69.0M vs $-157.1M). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (18.6% CAGR vs -9.6%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Forestar Group Inc. is a residential lot development company based in Arlington, Texas. The company has operations in 51 markets in 21 states and delivered 11,518 residential lots during the twelve-month period ended December 31, 2020. The company is publicly traded on the New York Stock Exchange and in October 2017 became a majority-owned subsidiary of D.R. Horton, Inc., the largest homebuilder by volume in the United States since 2002. The company primarily acquires entitled real estate and...

CLOV vs FOR — Head-to-Head

Bigger by revenue
CLOV
CLOV
1.8× larger
CLOV
$487.7M
$273.0M
FOR
Growing faster (revenue YoY)
CLOV
CLOV
+35.7% gap
CLOV
44.7%
9.0%
FOR
Higher net margin
FOR
FOR
15.8% more per $
FOR
5.6%
-10.1%
CLOV
More free cash flow
CLOV
CLOV
$88.1M more FCF
CLOV
$-69.0M
$-157.1M
FOR
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
18.6%
-9.6%
FOR

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CLOV
CLOV
FOR
FOR
Revenue
$487.7M
$273.0M
Net Profit
$-49.3M
$15.4M
Gross Margin
20.1%
Operating Margin
-10.1%
7.6%
Net Margin
-10.1%
5.6%
Revenue YoY
44.7%
9.0%
Net Profit YoY
-123.2%
-6.7%
EPS (diluted)
$0.30

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
FOR
FOR
Q4 25
$487.7M
$273.0M
Q3 25
$496.6M
$670.5M
Q2 25
$477.6M
$390.5M
Q1 25
$462.3M
$351.0M
Q4 24
$337.0M
$250.4M
Q3 24
$331.0M
$551.3M
Q2 24
$356.3M
$318.4M
Q1 24
$346.9M
$333.8M
Net Profit
CLOV
CLOV
FOR
FOR
Q4 25
$-49.3M
$15.4M
Q3 25
$-24.4M
$86.9M
Q2 25
$-10.6M
$32.9M
Q1 25
$-1.3M
$31.6M
Q4 24
$-22.1M
$16.5M
Q3 24
$-9.2M
$81.5M
Q2 24
$7.4M
$38.7M
Q1 24
$-19.2M
$45.0M
Gross Margin
CLOV
CLOV
FOR
FOR
Q4 25
20.1%
Q3 25
22.3%
Q2 25
20.4%
Q1 25
22.6%
Q4 24
22.0%
Q3 24
24.5%
23.9%
Q2 24
30.3%
22.5%
Q1 24
23.6%
24.9%
Operating Margin
CLOV
CLOV
FOR
FOR
Q4 25
-10.1%
7.6%
Q3 25
-4.9%
16.9%
Q2 25
-2.2%
11.2%
Q1 25
-0.3%
11.6%
Q4 24
-6.4%
8.7%
Q3 24
-2.7%
19.7%
Q2 24
2.0%
16.2%
Q1 24
-6.5%
17.6%
Net Margin
CLOV
CLOV
FOR
FOR
Q4 25
-10.1%
5.6%
Q3 25
-4.9%
13.0%
Q2 25
-2.2%
8.4%
Q1 25
-0.3%
9.0%
Q4 24
-6.6%
6.6%
Q3 24
-2.8%
14.8%
Q2 24
2.1%
12.2%
Q1 24
-5.5%
13.5%
EPS (diluted)
CLOV
CLOV
FOR
FOR
Q4 25
$0.30
Q3 25
$1.70
Q2 25
$0.65
Q1 25
$0.62
Q4 24
$0.32
Q3 24
$1.59
Q2 24
$0.76
Q1 24
$0.89

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
FOR
FOR
Cash + ST InvestmentsLiquidity on hand
$78.3M
$211.7M
Total DebtLower is stronger
$793.2M
Stockholders' EquityBook value
$308.7M
$1.8B
Total Assets
$541.0M
$3.2B
Debt / EquityLower = less leverage
0.44×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
FOR
FOR
Q4 25
$78.3M
$211.7M
Q3 25
$379.2M
Q2 25
$189.2M
Q1 25
$174.3M
Q4 24
$194.5M
$132.0M
Q3 24
$288.0M
$481.2M
Q2 24
$254.8M
$359.2M
Q1 24
$208.3M
$416.2M
Total Debt
CLOV
CLOV
FOR
FOR
Q4 25
$793.2M
Q3 25
$802.7M
Q2 25
$872.8M
Q1 25
$872.5M
Q4 24
$806.8M
Q3 24
$706.4M
Q2 24
$706.1M
Q1 24
$705.7M
Stockholders' Equity
CLOV
CLOV
FOR
FOR
Q4 25
$308.7M
$1.8B
Q3 25
$340.9M
$1.8B
Q2 25
$344.2M
$1.7B
Q1 25
$336.1M
$1.6B
Q4 24
$341.1M
$1.6B
Q3 24
$342.2M
$1.6B
Q2 24
$324.9M
$1.5B
Q1 24
$292.5M
$1.5B
Total Assets
CLOV
CLOV
FOR
FOR
Q4 25
$541.0M
$3.2B
Q3 25
$559.7M
$3.1B
Q2 25
$575.0M
$3.1B
Q1 25
$583.7M
$3.0B
Q4 24
$580.7M
$3.0B
Q3 24
$653.0M
$2.8B
Q2 24
$674.2M
$2.7B
Q1 24
$671.8M
$2.6B
Debt / Equity
CLOV
CLOV
FOR
FOR
Q4 25
0.44×
Q3 25
0.45×
Q2 25
0.52×
Q1 25
0.53×
Q4 24
0.50×
Q3 24
0.44×
Q2 24
0.47×
Q1 24
0.48×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
FOR
FOR
Operating Cash FlowLast quarter
$-66.9M
$-157.0M
Free Cash FlowOCF − Capex
$-69.0M
$-157.1M
FCF MarginFCF / Revenue
-14.1%
-57.5%
Capex IntensityCapex / Revenue
0.4%
0.0%
Cash ConversionOCF / Net Profit
-10.19×
TTM Free Cash FlowTrailing 4 quarters
$-69.2M
$93.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
FOR
FOR
Q4 25
$-66.9M
$-157.0M
Q3 25
$12.1M
$256.3M
Q2 25
$5.4M
$15.8M
Q1 25
$-16.3M
$-19.8M
Q4 24
$34.8M
$-450.0M
Q3 24
$50.0M
$119.2M
Q2 24
$44.8M
$-61.7M
Q1 24
$25.9M
$-59.2M
Free Cash Flow
CLOV
CLOV
FOR
FOR
Q4 25
$-69.0M
$-157.1M
Q3 25
$11.4M
$255.6M
Q2 25
$4.8M
$15.0M
Q1 25
$-16.5M
$-20.5M
Q4 24
$33.3M
Q3 24
$49.6M
$118.4M
Q2 24
$44.4M
$-62.3M
Q1 24
$25.5M
$-59.8M
FCF Margin
CLOV
CLOV
FOR
FOR
Q4 25
-14.1%
-57.5%
Q3 25
2.3%
38.1%
Q2 25
1.0%
3.8%
Q1 25
-3.6%
-5.8%
Q4 24
9.9%
Q3 24
15.0%
21.5%
Q2 24
12.5%
-19.6%
Q1 24
7.3%
-17.9%
Capex Intensity
CLOV
CLOV
FOR
FOR
Q4 25
0.4%
0.0%
Q3 25
0.1%
0.1%
Q2 25
0.1%
0.2%
Q1 25
0.0%
0.2%
Q4 24
0.5%
0.0%
Q3 24
0.1%
0.1%
Q2 24
0.1%
0.2%
Q1 24
0.1%
0.2%
Cash Conversion
CLOV
CLOV
FOR
FOR
Q4 25
-10.19×
Q3 25
2.95×
Q2 25
0.48×
Q1 25
-0.63×
Q4 24
-27.27×
Q3 24
1.46×
Q2 24
6.04×
-1.59×
Q1 24
-1.32×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLOV
CLOV

Segment breakdown not available.

FOR
FOR

D.R.Horton Inc.$183.8M67%
Other$89.2M33%

Related Comparisons